You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Biomarker-Guided HF Therapy: Is It Cost-Effective?

  • Authors: James L. Januzzi, MD; Christopher M. O'Connor, MD
  • CME Released: 8/24/2012
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 8/24/2013
Start Activity


Target Audience and Goal Statement

This activity is intended for cardiologists, primary care physicians (PCPs), and emergency room physicians.

The goal of this activity is to examine the cost impact of using biomarkers along the continuum of care for heart failure.

Upon completion of this activity, participants will be able to:

  1. Assess the economic burdens associated with rehospitalization of heart failure patients
  2. Identify ways in which both optimized standard of care, and use of biomarkers can reduce re-hospitalization in heart failure patients


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Authors

  • James L. Januzzi, MD

    Associate Professor of Medicine, Harvard Medical School; Director, Cardiac Intensive Care Unit, Massachusetts General Hospital, Boston, Massachusetts

    Disclosures

    Disclosure: James L. Januzzi, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Critical Diagnostics; Roche.
    Received grants for clinical research from: Critical Diagnostics; Roche; Siemens AG.

    Dr Januzzi does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Januzzi does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Christopher O'Connor, MD

    Professor of Medicine; Director of Heart Center; Executive Director of Cardiology, Division of Cardiovascular Medicine, Duke Clinical Research Institute, Durham, North Carolina

    Disclosures

    Disclosure: Christopher M. O'Connor, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Cortex Pharmaceuticals, Inc.; GE Healthcare; Amgen Inc.; Pfizer Inc; Novartis Phamaceuticals Corporation; Ikaria, Inc.; HeartWare International, Inc.; Actelion Pharmaceuticals, Ltd; HeartWare International, Inc.; F. Hoffmann-La Roche, Ltd; Cortex Pharmaceuticals, Inc.; Nile Therapeutics, Inc.; ResMed; POZEN Inc.; Warburg Pincus, LLC
    Received grants for clinical research from: Amgen Inc.; Astellas Pharma, Inc.; BG Medicine; Critical Diagnostics; GE Healthcare; Gilead Sciences, Inc.; Johnson & Johnson Pharmaceutical Research & Development, LLC; Otsuka Pharmaceutical Co., Ltd.; Roche Diagnostics

    Dr O'Connor does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr O'Connor does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editors

  • Ronald K. Miller, PhD

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Ronald K. Miller, PhD, has disclosed no relevant financial relationships.

  • Colleen Quinn

    Clinical Editor, Medscape, LLC

    Disclosures

    Disclosure: Colleen Quinn has disclosed no relevant financial relationships.

CME Reviewer

  • Nafeez Zawahir, MD

    CME Clinical Director, Medscape, LLC

    Disclosures

    Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Biomarker-Guided HF Therapy: Is It Cost-Effective?

Authors: James L. Januzzi, MD; Christopher M. O'Connor, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME Released: 8/24/2012

Valid for credit through: 8/24/2013

processing....

Abbreviations

ACE = angiotensin-converting enzyme
ACO = Accountable Care Organization
ADHERE = Acute Decompensated Heart Failure National Registry
AF = atrial fibrillation
ARB = angiotensin receptor blocker
ASCEND = Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure
BNP = brain natriuretic peptide
CI = confidence interval
COPD = chronic obstructive pulmonary disease
CRT = cardiac resynchronization therapy
CV = cardiovascular
eGFR = estimated glomerular filtration rate
HF = heart failure
GUIDE-IT = GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment
iBNP = immunoreactive BNP
ICD = implantable cardioverter defibrillator
ICER = incremental cost-effectiveness ratio
IMPROVE-CHF = The Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting
IV = intravenous
LVEF = left ventricular ejection fraction
NIH = National Institutes of Health
NT-proBNP = N-terminal prohormone of brain natriuretic peptide
NYHA = Hew York Heart Association
OPTIMIZE-HF = Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure
PRIDE = ProBNP Investigation of Dyspnea in the Emergency Department
PROTECT = Use of NT-proBNP Testing to Guide Heart Failure Therapy in the Outpatient Setting
SOC = standard of care
TIME-CHF = Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure

« Return to: Biomarker-Guided HF Therapy: Is It Cost-Effective?
  • Print